CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats Do you believe it? #ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP